Brokerages Set Savara Inc. (NASDAQ:SVRA) Price Target at $8.86

Savara Inc. (NASDAQ:SVRA) has been given a consensus recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.8571.

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Oppenheimer set a $10.00 price objective on Savara in a report on Tuesday, December 23rd. UBS Group set a $10.00 target price on shares of Savara in a research report on Tuesday, December 23rd. Citizens Jmp decreased their price objective on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 13th. Finally, Wells Fargo & Company upped their price target on Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, December 18th.

Savara Trading Down 4.0%

Shares of SVRA stock opened at $5.27 on Monday. Savara has a 12 month low of $1.89 and a 12 month high of $7.01. The business’s 50 day moving average is $5.73 and its two-hundred day moving average is $4.89. The company has a market cap of $1.07 billion, a PE ratio of -9.94 and a beta of 0.31. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.32.

Hedge Funds Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. F m Investments LLC increased its position in Savara by 41.2% during the second quarter. F m Investments LLC now owns 314,846 shares of the company’s stock worth $718,000 after buying an additional 91,830 shares during the last quarter. Swedbank AB bought a new position in shares of Savara during the third quarter worth approximately $1,964,000. Geode Capital Management LLC increased its position in shares of Savara by 5.2% in the second quarter. Geode Capital Management LLC now owns 2,970,183 shares of the company’s stock worth $6,773,000 after purchasing an additional 147,946 shares during the period. Affinity Asset Advisors LLC acquired a new position in Savara during the second quarter valued at approximately $1,140,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Savara during the 2nd quarter valued at $69,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.